Login to Your Account



Ponatinib Findings Power Financing

Post-ASH, Ariad Prices Public Offering, Aims to Raise $224M

By Marie Powers
Staff Writer

Friday, December 16, 2011

On Wednesday, Ariad Pharmaceuticals Inc. filed a shelf registration covering stock, debt securities, warrants and units. The company didn't leave investors in suspense for long. A day later, the company priced an underwritten public offering of 21.5 million shares of common stock at Wednesday's closing price of $10.42 per share, a discount of just 5.4 percent from Tuesday's closing price of $11.01.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription